Predictive Value of Metabolic Parameters Derived from Preoperative F-FDG Positron Emission Tomography/computed Tomography for Brain Metastases in Patients with Surgically Resected Non-small Cell Lung Cancer

Overview

Journal Quant Imaging Med Surg

Specialty Radiology

Date 2023 Dec 18

PMID 38106281

Authors

Jingjie Shang

Yongjin Tang

Bingyu Ran

Biao Wu

Yingxin Li

Yong Cheng

Bin Guo

Jian Gong

Lu Wang

Xueying Ling

Hao Xu

Affiliations

Soon will be listed here.

Abstract

Background: Brain metastases (BMs) are common complications in patients with non-small cell lung cancer (NSCLC). The purpose of this study was to investigate whether the metabolic parameters derived from preoperative F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) can predict BM development in patients with surgically resected NSCLC.

Methods: We retrospectively reviewed 128 consecutive patients with stage I-IIIA NSCLC who underwent F-FDG PET/CT before curative surgery at The First Affiliated Hospital of Jinan University between November 2012 and October 2021. By drawing a volume of interest (VOI), the maximum standardized uptake values (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of the primary tumor as well as the mean SUV (SUV) of the liver and arterial blood were measured. The tumor-to-liver SUV ratio (TLR) and tumor-to-blood SUV ratio (TBR) were also calculated. Receiver operating characteristic curve analysis was used to determine the best cut-off values for positron emission tomography (PET) parameters to predict BM-free survival, and Cox proportional hazards regression analysis was used to assess the predictive value of clinical variables and PET parameters.

Results: The median follow-up duration for survival patients was 23.4 months, and 15 patients (11.7%) experienced BM as the initial relapse site. The cumulative rates of BM over the course of 1, 2, and 5 years were 4.5%, 10.5%, and 17.5%, respectively. The optimal cut-off values for the prediction of BM-free survival were 7.7, 4.9, and 4.5 for SUV, TLR, and TBR, and 5.5 mL and 16.1 for MTV and TLG, respectively. In the Cox proportional hazards model, the risk of BM was significantly associated with TLR [hazard ratio (HR) =10.712; 95% confidence interval (CI): 2.958-38.801; P<0.001] and MTV (HR =3.150; 95% CI: 0.964-10.293; P=0.020) after adjusting for tumor stage, clinicopathological factors, and other PET parameters.

Conclusions: Preoperative TLR and MTV of the primary tumor may be helpful in predicting BM development in patients with surgically resected NSCLC. Tumor metabolic parameters may potentially be used to stratify the risk of BM and determine individualized surveillance strategies.

References

Gao Y, Kuksis M, Said B, Chehade R, Kiss A, Tran W . Treatment Patterns and Outcomes of Women with Symptomatic and Asymptomatic Breast Cancer Brain Metastases: A Single-Center Retrospective Study. Oncologist. 2021; 26(11):e1951-e1961. PMC: 8571756. DOI: 10.1002/onco.13965. View

Du S, Sun H, Gao S, Xin J, Lu Z . Metabolic parameters with different thresholds for evaluating tumor recurrence and their correlations with hematological parameters in locally advanced squamous cell cervical carcinoma: an observational F-FDG PET/CT study. Quant Imaging Med Surg. 2019; 9(3):440-452. PMC: 6462570. DOI: 10.21037/qims.2019.02.09. View

Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R . EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging. 2017; 44(Suppl 1):17-31. PMC: 5541084. DOI: 10.1007/s00259-017-3740-2. View

Ando T, Kage H, Saito M, Amano Y, Goto Y, Nakajima J . Early stage non-small cell lung cancer patients need brain imaging regardless of symptoms. Int J Clin Oncol. 2018; 23(4):641-646. DOI: 10.1007/s10147-018-1254-y. View

Zhang Q, Cai X, Feng W, Yu W, Fu X . Risk factors of brain metastases as initial failure in completely resected stage IIIA(N2) non-small cell lung cancer. Ann Transl Med. 2020; 8(6):374. PMC: 7186613. DOI: 10.21037/atm.2020.02.72. View

Ding X, Dai H, Hui Z, Ji W, Liang J, Lv J . Risk factors of brain metastases in completely resected pathological stage IIIA-N2 non-small cell lung cancer. Radiat Oncol. 2012; 7:119. PMC: 3430600. DOI: 10.1186/1748-717X-7-119. View

Shang J, Ling X, Zhang L, Tang Y, Xiao Z, Cheng Y . Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2016; 43(11):1945-53. DOI: 10.1007/s00259-016-3420-7. View

Hofheinz F, Li Y, Steffen I, Lin Q, Lili C, Hua W . Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2019; 46(7):1485-1494. DOI: 10.1007/s00259-019-04307-6. View

Chou H, Lin K, Huang H, Lin L, Chen Y, Wu T . Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer. Eur Radiol. 2021; 31(10):8021-8029. DOI: 10.1007/s00330-021-07801-4. View

10.

Hubbs J, Boyd J, Hollis D, Chino J, Saynak M, Kelsey C . Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer. 2010; 116(21):5038-46. DOI: 10.1002/cncr.25254. View

11.

Peters S, Bexelius C, Munk V, Leighl N . The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev. 2016; 45:139-62. DOI: 10.1016/j.ctrv.2016.03.009. View

12.

Vogelbaum M, Brown P, Messersmith H, Brastianos P, Burri S, Cahill D . Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2021; 40(5):492-516. DOI: 10.1200/JCO.21.02314. View

13.

UyBico S, Wu C, Suh R, Le N, Brown K, Krishnam M . Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls. Radiographics. 2010; 30(5):1163-81. DOI: 10.1148/rg.305095166. View

14.

Singh Achrol A, Rennert R, Anders C, Soffietti R, Ahluwalia M, Nayak L . Brain metastases. Nat Rev Dis Primers. 2019; 5(1):5. DOI: 10.1038/s41572-018-0055-y. View

15.

Sun F, Chen Y, Chen X, Sun X, Xing L . CT-based radiomics for predicting brain metastases as the first failure in patients with curatively resected locally advanced non-small cell lung cancer. Eur J Radiol. 2020; 134:109411. DOI: 10.1016/j.ejrad.2020.109411. View

16.

Hanzly M, Abbotoy D, Creighton T, Diorio G, Mehedint D, Murekeyisoni C . Early identification of asymptomatic brain metastases from renal cell carcinoma. Clin Exp Metastasis. 2015; 32(8):783-8. DOI: 10.1007/s10585-015-9748-8. View

17.

Hyun S, Choi J, Kim K, Kim J, Shim Y, Um S . Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg. 2012; 257(2):364-70. DOI: 10.1097/SLA.0b013e318262a6ec. View

18.

Xu W, Yu S, Ma Y, Liu C, Xin J . Effect of different segmentation algorithms on metabolic tumor volume measured on 18F-FDG PET/CT of cervical primary squamous cell carcinoma. Nucl Med Commun. 2017; 38(3):259-265. PMC: 5318156. DOI: 10.1097/MNM.0000000000000641. View

19.

Li X, Shi Y, Niu R, Shao X, Wang J, Shao X . Risk analysis in peripheral clinical T1 non-small cell lung cancer correlations between tumor-to-blood standardized uptake ratio on F-FDG PET-CT and primary tumor pathological invasiveness: a real-world observational study. Quant Imaging Med Surg. 2022; 12(1):159-171. PMC: 8666728. DOI: 10.21037/qims-21-394. View

20.

Venur V, Chukwueke U, Lee E . Advances in Management of Brain and Leptomeningeal Metastases. Curr Neurol Neurosci Rep. 2020; 20(7):26. DOI: 10.1007/s11910-020-01039-1. View